Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1148/radiol.2443060926
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thukral, A.
Right arrow Articles by Swain, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thukral, A.
Right arrow Articles by Swain, S. M.
(Radiology 2007;244:727-735.)
© RSNA, 2007

Breast Imaging

Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience1

Arpi Thukral, MD, David M. Thomasson, PhD, Catherine K. Chow, MD, Reyes Eulate, MD, Suparna B. Wedam, MD, Sandeep N. Gupta, PhD, Betty J. Wise, BS, RT(R)MR, Seth M. Steinberg, PhD, David J. Liewehr, PhD, Peter L. Choyke, MD, and Sandra M. Swain, MD 2

1 From the Medical Oncology Branch (A.T., S.B.W., S. M. Swain), Molecular Imaging Program (R.E., P.L.C.), and Biostatistics and Data Management Section (S. M. Steinberg, D.J.L.), Center for Cancer Research, National Cancer Institute; and Diagnostic Radiology Department, Warren G. Magnuson Clinical Center (D.M.T., C.K.C., B.J.W.), National Institutes of Health, 8901 Wisconsin Ave, Bldg 8, Room 5101, Bethesda, MD 20889-5015; and GE Healthcare Technologies, Hanover, Md (S.N.G.). Received June 2, 2006; revision requested August 1; revision received October 12; accepted November 3; final version accepted January 12, 2007. A.T. supported by the Clinical Research Training Program at National Institutes of Health (NIH), a public-private partnership supported jointly by the NIH, and a grant to the Foundation for the NIH from Pfizer Pharmaceuticals Group. Supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Address correspondence to S. M. Swain (e-mail: Sandra.M.Swain{at}Medstar.net).

Purpose: To retrospectively compare three dynamic contrast material–enhanced magnetic resonance (MR) imaging (dynamic MR imaging) analytic methods to determine the parameter or combination of parameters most strongly associated with changes in tumor microvasculature during treatment with bevacizumab alone and bevacizumab plus chemotherapy in patients with inflammatory or locally advanced breast cancer.

Materials and Methods: This study was conducted in accordance with the institutional review board of the National Cancer Institute and was compliant with the Privacy Act of 1974. Informed consent was obtained from all patients. Patients with inflammatory or locally advanced breast cancer were treated with one cycle of bevacizumab alone (cycle 1) followed by six cycles of combination bevacizumab and chemotherapy (cycles 2–7). Serial dynamic MR images were obtained, and the kinetic parameters measured by using three dynamic analytic MR methods (heuristic, Brix, and general kinetic models) and two region-of-interest strategies were compared by using two-sided statistical tests. A P value of .01 was required for significance.

Results: In 19 patients, with use of a whole-tumor region of interest, the authors observed a significant decrease in the median values of three parameters measured from baseline to cycle 1: forward transfer rate constant (Ktrans) (–34% relative change, P = .003), backflow compartmental rate constant extravascular and extracellular to plasma (Kep) (–15% relative change, P < .001), and integrated area under the gadolinium concentration curve (IAUGC) at 180 seconds (–23% relative change, P = .009). A trend toward differences in the heuristic slope of the washout curve between responders and nonresponders to therapy was observed after cycle 1 (bevacizumab alone, P = .02). The median relative change in slope of the wash-in curve from baseline to cycle 4 was significantly different between responders and nonresponders (P = .009).

Conclusion: The dynamic contrast-enhanced MR parameters Ktrans, Kep, and IAUGC at 180 seconds appear to have the strongest association with early physiologic response to bevacizumab.

Clinical trial registration no. NCT00016549 [ClinicalTrials.gov]

© RSNA, 2007




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Kim, L. Loevner, H. Quon, E. Sherman, G. Weinstein, A. Kilger, and H. Poptani
Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck
Clin. Cancer Res., February 1, 2009; 15(3): 986 - 994.
[Abstract] [Full Text] [PDF]